Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
First Claim
1. A therapeutic regimen for improving survivability or quality of life of a patient in need thereof having elevated C-reactive protein levels, and decreased serum albumin levels, comprising administering a first composition which comprises an amount of an anti-interleukin-6 (“
- IL-6”
), antibody or anti-IL-6 antibody fragment effective to reduce CRP levels and/or increase serum albumin levels, wherein the antibody or antibody fragment has the variable light (VL) polypeptide of SEQ ID NO;
20 and the VH polypeptide of SEQ ID NO;
19, and further comprising administering a second active agent other than said anti-IL-6 antibody or anti-IL-6 antibody fragment which second active agent is comprised in the first composition or is comprised in a second composition.
7 Assignments
0 Petitions
Accused Products
Abstract
The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient'"'"'s Glasgow Prognostic Score will be increased and survivability will preferably be improved.
185 Citations
15 Claims
-
1. A therapeutic regimen for improving survivability or quality of life of a patient in need thereof having elevated C-reactive protein levels, and decreased serum albumin levels, comprising administering a first composition which comprises an amount of an anti-interleukin-6 (“
- IL-6”
), antibody or anti-IL-6 antibody fragment effective to reduce CRP levels and/or increase serum albumin levels, wherein the antibody or antibody fragment has the variable light (VL) polypeptide of SEQ ID NO;
20 and the VH polypeptide of SEQ ID NO;
19, and further comprising administering a second active agent other than said anti-IL-6 antibody or anti-IL-6 antibody fragment which second active agent is comprised in the first composition or is comprised in a second composition. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
- IL-6”
Specification